These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 21074499)

  • 1. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.
    Chen E; Beer PA; Godfrey AL; Ortmann CA; Li J; Costa-Pereira AP; Ingle CE; Dermitzakis ET; Campbell PJ; Green AR
    Cancer Cell; 2010 Nov; 18(5):524-35. PubMed ID: 21074499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
    Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A
    Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical requirement for Stat5 in a mouse model of polycythemia vera.
    Yan D; Hutchison RE; Mohi G
    Blood; 2012 Apr; 119(15):3539-49. PubMed ID: 22144185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.
    Li J; Kent DG; Godfrey AL; Manning H; Nangalia J; Aziz A; Chen E; Saeb-Parsy K; Fink J; Sneade R; Hamilton TL; Pask DC; Silber Y; Zhao X; Ghevaert C; Liu P; Green AR
    Blood; 2014 May; 123(20):3139-51. PubMed ID: 24692758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation.
    Meyer T; Ruppert V; Görg C; Neubauer A
    Int J Hematol; 2010 Jan; 91(1):117-20. PubMed ID: 20013324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
    Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
    APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct effects of V617F and exon12-mutated JAK2 expressions on erythropoiesis in a human induced pluripotent stem cell (iPSC)-based model.
    Nilsri N; Jangprasert P; Pawinwongchai J; Israsena N; Rojnuckarin P
    Sci Rep; 2021 Mar; 11(1):5255. PubMed ID: 33664283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
    Akada H; Yan D; Zou H; Fiering S; Hutchison RE; Mohi MG
    Blood; 2010 Apr; 115(17):3589-97. PubMed ID: 20197548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-phenotype interactions in the myeloproliferative neoplasms.
    Godfrey AL; Green AR
    Hematol Oncol Clin North Am; 2012 Oct; 26(5):993-1015. PubMed ID: 23009934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
    Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
    Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.
    Lussana F; Carobbio A; Salmoiraghi S; Guglielmelli P; Vannucchi AM; Bottazzi B; Leone R; Mantovani A; Barbui T; Rambaldi A
    J Hematol Oncol; 2017 Feb; 10(1):54. PubMed ID: 28228104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinguishing essential thrombocythemia
    Silver RT; Krichevsky S
    Haematologica; 2019 Nov; 104(11):2200-2205. PubMed ID: 30948488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutated JAK2 signal transduction in human induced pluripotent stem cell (iPSC)-derived megakaryocytes.
    Pawinwongchai J; Jangprasert P; Nilsri N; Israsena N; Rojnuckarin P
    Platelets; 2022 Jul; 33(5):700-708. PubMed ID: 34749590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation.
    Stetka J; Vyhlidalova P; Lanikova L; Koralkova P; Gursky J; Hlusi A; Flodr P; Hubackova S; Bartek J; Hodny Z; Divoky V
    Oncogene; 2019 Jul; 38(28):5627-5642. PubMed ID: 30967632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.
    Godfrey AL; Chen E; Pagano F; Ortmann CA; Silber Y; Bellosillo B; Guglielmelli P; Harrison CN; Reilly JT; Stegelmann F; Bijou F; Lippert E; McMullin MF; Boiron JM; Döhner K; Vannucchi AM; Besses C; Campbell PJ; Green AR
    Blood; 2012 Sep; 120(13):2704-7. PubMed ID: 22898600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.
    Berkofsky-Fessler W; Buzzai M; Kim MK; Fruchtman S; Najfeld V; Min DJ; Costa FF; Bischof JM; Soares MB; McConnell MJ; Zhang W; Levine R; Gilliland DG; Calogero R; Licht JD
    Clin Cancer Res; 2010 Sep; 16(17):4339-52. PubMed ID: 20601445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
    Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms.
    Wiśniewska-Chudy E; Szylberg Ł; Dworacki G; Mizera-Nyczak E; Marszałek A
    Oncol Rep; 2017 Apr; 37(4):2295-2307. PubMed ID: 28260027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.
    Marty C; Lacout C; Martin A; Hasan S; Jacquot S; Birling MC; Vainchenker W; Villeval JL
    Blood; 2010 Aug; 116(5):783-7. PubMed ID: 20472827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.